TokenPost·
Altimmune Reports $480 Million in Cash as Third-Quarter Loss Widens
The company expects 52-week results from its Phase 3 PERFORMA trial in 2029 and RESTORE data in the second half of 2027.
More news
- TokenPostApplied Optoelectronics Posts $269.9 Million in Q3 Revenue
- crypto.newsGemini reportedly sells UK and EU units to KAST for under $10M
- Crypto BriefingCerebras Systems guides fourth-quarter core revenue to $310M-$330M, well above estimates
- TokenPostDaly Says AI Demand May Ease as Chip Price Concerns Persist
- TokenPostFed Tentatively Schedules Seven Rate Decisions for 2027
- Crypto BriefingApplied Materials posts $10.41 billion fourth quarter as revenue jumps 53%